Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cetirizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.98 |
| ▸ | DRD3 | P35462 | 5/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | HRH2 | P25021 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | TEK | Q02763 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 4/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | DRD4 | P21917 | 1/20 | 0.73 |
| ▸ | HTR7 | P34969 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levocetirizine SCHEMBL4914 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL2455487 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Levocetirizine SCHEMBL5935097 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL5526985 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL4176 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL13724610 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL1231124 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL2430457 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL41107 | 0.98 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A | |
| Cetirizine SCHEMBL5520719 | 0.98 | HRH1 (1.00) | DRD3HRH1USP2HRH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102321047-B | Preparation method of cetirizine hydrochloride | ZHEJIANG ZHEBEI PHARMACEUTICAL INDUSTRY CO LTD | 2013-09-18 | — | — | CN | claimed |
| CN-102321047-A | Preparation method of cetirizine hydrochloride | ZHEJIANG ZHEBEI PHARMACEUTICAL INDUSTRY CO LTD | 2012-01-18 | — | — | CN | claimed |
| CN-118203584-A | Combined pharmaceutical composition for resisting chronic myelogenous leukemia and application thereof | 厦门大学附属第一医院 | 2024-06-18 | — | — | CN | disclosed |
| CN-117209454-A | Novel levocetirizine sodium crystal form and preparation method thereof | 迪嘉药业集团股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-102321047-B | Preparation method of cetirizine hydrochloride | ZHEJIANG ZHEBEI PHARMACEUTICAL INDUSTRY CO LTD | 2013-09-18 | — | — | CN | disclosed |
| CN-102321047-B | Preparation method of cetirizine hydrochloride | ZHEJIANG ZHEBEI PHARMACEUTICAL INDUSTRY CO LTD | 2013-09-18 | — | — | CN | disclosed |
| CN-102321047-A | Preparation method of cetirizine hydrochloride | ZHEJIANG ZHEBEI PHARMACEUTICAL INDUSTRY CO LTD | 2012-01-18 | — | — | CN | disclosed |
| CN-102321047-A | Preparation method of cetirizine hydrochloride | ZHEJIANG ZHEBEI PHARMACEUTICAL INDUSTRY CO LTD | 2012-01-18 | — | — | CN | disclosed |
| US-6908999-B2 | Hydrolysis of N,N-disubstituted (2-(4-(alpha-phenyl-p-chloro-benzyl)piperazin-1-yl)ethoxy)acetamide, to form cetirizine and salts, used as antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2005-06-21 | — | — | US | disclosed |
| EP-1233954-B1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-10-20 | — | — | EP | disclosed |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | CMA1, NAT1, CPN1 | HRH1 8/4885DRD3 2986/4885USP2 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.